Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study.
The researchers from King's College London in the United Kingdom also found that most systemic side effects -- meaning side effects excluding where the injection took place -- peaked within the first 24 hours following vaccination and usually lasted 1-2 days.
Dr Malhotra, who has demanded a full safety review into the use of AstraZeneca's Covid vaccine, told PTI Covishield "should never have been rolled out in the country in the first place".
'Once DCGI will give us the permission to restart the trials in India, we will resume the trials,' Serum Institute of India (SII) said in a statement.
For patients, the immediate impact is a reduction in the final cost of therapies that often run into lakhs per month.
The comments came after AstraZeneca and Oxford University acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine.
'Our study shows a greater risk reduction for people who received an mRNA vaccine after having received a first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses,' Nordstrom said.
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of Oxford/AstraZeneca's Covid-19 vaccine, administered in India as Covishield, over feared serious side effects such as heart attack and stroke.
The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.
The nature of the adverse reaction and when the development took place were not initially clear, although the participant is expected to recover, said an individual familiar with the matter.
The world is learning about a side effect of the COVID vaccine called Thrombosis with Thrombocytopenia Syndrome, he said.
The DCGI also directed Serum Institute of India to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
According to the study, 'mixed' schedules of these vaccines induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart.
The expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine.
India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.
There is confusion over the United Kingdom government's vaccine recognition process for Indian travellers as even though Oxford/AstraZeneca Covishield, the India-manufactured Oxford/AstraZeneca COVID-19 vaccine, is on an updated international travel advisory, India is not yet on a list of 17 approved countries.
If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.
Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.
"I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said in a tweet.
The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.
There is a decisive shift in how cancer may soon be confronted and, hopefully, defeated.
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
"Pfizer's proposal would dramatically dilute AstraZeneca shareholders' exposure to our unique pipeline and would create risks around its delivery," Chairman Leif Johansson said.
However, in two different dose regimens, the vaccine's efficacy was 90 per cent in one and 62 per cent in the other.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.
The show-cause notice was issued following reports that human trials of the most promising COVID-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a United Kingdom participant had an adverse reaction to it.
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
In the next two weeks, the United States will detail plans to equitably distribute about 80 million (8 crore) COVID-19 vaccine doses globally without 'political requirements' of those receiving them, Secretary of State Antony Blinken has said.
Initially, we will look to take a small batch of a few hundred students, with a plan to increase this to 5,000 students in the next five years, and eventually 10,000 by 2036.'
"We have started the phase-III trials of the vaccine (candidate Covishield). We will administer dose to 150 to 200 volunteers," said Dr Muralidhar Tambe, Dean, Sassoon General Hospital.
Poonawalla, however, did not specify the quantity of the doses that will be kept for the community, which is grappling with a shrinking population.
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
The Oxford vaccine, which also has a tie-up with the Serum Institute of India, is expected to win approval in the UK before Thursday, speeding up the provision of the jab to the most vulnerable groups.
"The vaccination schedule is considered complete 28 days after the administration of a dose for Janssen vaccine and 7 days after administration of a second dose for other vaccines (Pfizer / Comirnaty, Moderna, AstraZeneca/Vaxzevria/Covishield)," the statement added.
50 lakh doses of 'Covishield' vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in COVID-19 cases, official sources said.
The economics and pricing of the Covishield vaccines and the government's own decision to pay higher prices raise more than a few questions, observes Prosenjit Datta.
The Medicines and Healthcare Regulatory Agency, which had been formally tasked by the UK government last month with the process of clearance after the jab emerged "safe and effective" against the novel coronavirus in human trials, is expected to authorise the vaccine by December 28 or 29 after the final data is provided on Monday, 'The Daily Telegraph' quoted senior government sources as indicating.
Pune's Serum Institute of India, the world's largest vaccine maker by volume, is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222 with CEO Adar Poonawalla stating he would start manufacturing at personal risk.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.
Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.
